Matrix protein compositions for modulating immune response

Use according to any of the preceding claims, wherein said active enamel substance and/or said preparation comprised in said pharmaceutical composition modulates the conception of T-helper cell activation in said mammal.

Use according to any of the preceding claims, wherein said active enamel substance and/or said preparation comprised in said pharmaceutical composition modulates inter- and/or intra-cellular signalling substances.

Use according to any of the preceding claims, wherein said active enamel substance and/or said preparation comprised in said pharmaceutical composition modulates a cellular signalling cascade involved in said immune mechanism of said mammal.

Use according to any of the preceding claims, wherein said pharmaceutical composition is administered systemically.

Use according to any of the preceding claims, wherein said active enamel substance is an enamel matrix, enamel matrix derivative and/or enamel matrix protein.

Use according to any of the preceding claims, wherein said active enamel substance is selected from the group consisting of enameling, amelogenins, non-amelogenins, proline-rich non-amelogenins, tuftelins, derivatives thereof and mixtures thereof.

Use according to any of the preceding claims, wherein said active enamel substance is selected from the group consisting of amelogenins proteins and/or peptides, derivatives thereof and mixtures thereof.

Use according to any of the preceding claims, wherein said active enamel substance has a molecular weight of at the most about 120 kDa such as, at the most 100 kDa, 90 kDa, 80 kDa, 70 kDa or 60 kDa as determined by SDS PAGE electrophoresis.

Use according to any of the preceding claims, wherein said active enamel substance and/or said preparation comprises an amelogenin processing product of no more than 13 kDa.

Use according to any of the preceding claims, wherein said processed amelogenin product is comprised in the eluate represented by the third and/or fourth peak of an HPLC analysis of degraded amelogenin as shown in FIG. 2.

Use according to any of the preceding claims, wherein said processed amelogenin product is a 5 kDa polypeptide.

Use according to any of the preceding claims, wherein said active enamel substance has a molecular weight of up to about 40,000.

Use according to any of the preceding claims, wherein said active enamel substance has a molecular weight of between about 5,000 and about 25,000.

Use according to any of the preceding claims, wherein the major part of said active enamel substance has a molecular weight of about 20 kDa.

Use according to any of the preceding claims, wherein said preparation of an active enamel substance contains a mixture of active enamel substances with different molecular weights.

Use according to any of the preceding claims, wherein said preparation of an active enamel substance comprises at least two substances selected from the group consisting of amelogenins, proline-rich non-amelogenins, tuftelin, tuft proteins, serum proteins, salivary proteins, ameloblastin, sheathlin, and derivatives thereof.

Use according to any of the preceding claims, wherein the protein content of said active enamel substance in the preparation is in a range of from about 0.005% w/w to 100% w/w such as, about 5-99% w/w, about 10-95% w/w, about 15-90% w/w, about 20-90% w/w, about 30-90% w/w, about 40-85% w/w, about 50-80% w/w, about 60-70% w/w, about 70-90% w/w, or about 80-90% w/w.

Use according to any of the preceding claims, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.

A method for treating and/or preventing a condition in a mammal in need thereof by administering an effective amount of a pharmaceutical composition comprising an active enamel substance and/or a preparation of an active enamel substance, said condition being characterised by an imbalance in the immune response of said mammal due to external and/or internal stimuli.